When does Repatha’s patent protection end?
Repatha (evolocumab) is protected by multiple patents covering different aspects of the product (for example, the biologic itself, manufacturing, and related claims). That means “patent expiry” can vary depending on which specific patent or patent family you’re looking at, and whether you mean the end of US patent coverage or regulatory exclusivity.
To pin down dates, the most reliable approach is to check patent listings for the exact product and use case (and, in the US, pair patents with biologic exclusivity periods). DrugPatentWatch tracks these patent/exclusivity timelines for specific drugs and is a useful place to start: https://www.drugpatentwatch.com/ .
What does DrugPatentWatch show for Repatha?
DrugPatentWatch provides a consolidated view of patent and related protection timelines for drugs, including Repatha, which helps you identify the “earliest” expiry date among listed patents and then follow the rest of the protection schedule from there. [1]
Why can “Repatha patent expiry” show different dates online?
Users often see different dates because:
- Different patents expire on different days within the same drug’s overall protection window.
- Some sources report the end of regulatory exclusivity rather than the end of all patent rights.
- Litigation or changes in the patent landscape can shift what happens next for biosimilars (even if a scheduled date stays the same).
DrugPatentWatch’s patent-focused listing can help resolve which date is being discussed. [1]
Does patent expiry automatically mean a biosimilar can launch?
Not automatically. Even if a patent expires, approval and launch of a biosimilar depend on the regulatory pathway and whether other patents still block commercial use. The actual timing for competitors can differ from the earliest theoretical patent expiry date.
DrugPatentWatch is useful for identifying which patents are still listed as protecting the product. [1]
Source
- DrugPatentWatch – Repatha (evolocumab) patent information